CNBC: First Drug For Common Liver Disease Approved by FDA

114

FDA has approved a new drug from Madrigal Pharmaceuticals called Rezdiffra to treat nonalcoholic steatohepatitis (NASH) along with diet and exercise. NASH is a form of liver disease which impacts 6-8 million people in the US and is associated with other health issues including diabetes and high blood pressure. Rezidffra is the first drug used to treat NASH and doesn’t require a liver biopsy for patients to be eligible. 

To read the full article by Annika Kim Constantino and Ashley Capoot, click here. 

Comments are closed.

Skip to toolbar